Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Lagerbericht

Marktkapitalisierung: US$3.2b

Rhythm Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Rhythm Pharmaceuticals CEO ist David Meeker , ernannt in Jul 2020, hat eine Amtszeit von 4.33 Jahren. Die jährliche Gesamtvergütung beträgt $7.23M , bestehend aus 9.7% Gehalt und 90.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.29% der Aktien des Unternehmens, im Wert von $9.25M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4 Jahre bzw. 5.4 Jahre.

Wichtige Informationen

David Meeker

Geschäftsführender

US$7.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts9.7%
Amtszeit als Geschäftsführer4.3yrs
Eigentum des Geschäftsführers0.3%
Durchschnittliche Amtszeit des Managements4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.4yrs

Jüngste Management Updates

Recent updates

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Sep 23
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23
We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01
Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15
An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24
We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08
Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Meeker im Vergleich zu den Einnahmen von Rhythm Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$261m

Mar 31 2024n/an/a

-US$274m

Dec 31 2023US$7mUS$705k

-US$185m

Sep 30 2023n/an/a

-US$186m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023n/an/a

-US$181m

Dec 31 2022US$3mUS$652k

-US$181m

Sep 30 2022n/an/a

-US$181m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$166m

Dec 31 2021US$6mUS$630k

-US$70m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$15mUS$262k

-US$134m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$146m

Dec 31 2019US$287kn/a

-US$141m

Sep 30 2019n/an/a

-US$133m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$282kn/a

-US$74m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$53m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$268kn/a

-US$38m

Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD7.23M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD6.66M).

Entschädigung vs. Einkommen: DavidDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

David Meeker (70 yo)

4.3yrs

Amtszeit

US$7,230,457

Vergütung

Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
David Meeker
Chairman4.3yrsUS$7.23m0.29%
$ 9.3m
Hunter Smith
CFO & Treasurer7.3yrsUS$2.31m0.16%
$ 5.2m
Joseph Shulman
Chief Technical Officer4.3yrsUS$1.74m0.000050%
$ 1.6k
Yann Mazabraud
Executive VP & Head of International4.1yrsUS$1.74m0.057%
$ 1.8m
Jennifer Lee
Executive VP & Head of North America4yrsUS$2.11m0.011%
$ 363.1k
Christopher German
Corporate Controller1.7yrskeine Daten0.0013%
$ 42.1k
Alastair Garfield
Chief Scientific Officerless than a yearkeine Datenkeine Daten
David Connolly
Head of Investor Relations & Corporate Communicationsno datakeine Datenkeine Daten
Jim Flaherty
Senior VP & General Counsel4yrskeine Datenkeine Daten
Sarah Ryan
Vice President of Sales & Marketingno datakeine Datenkeine Daten
Pamela Cramer
Chief Human Resources Officer3.3yrskeine Daten0.022%
$ 715.3k
Elisabeth Cronert-Bendell
Senior VP & Head of Strategy2.8yrskeine Datenkeine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: RYTMDas Führungsteam des Unternehmens gilt als erfahren (4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
David Meeker
Chairman9yrsUS$7.23m0.29%
$ 9.3m
Christopher German
Corporate Controller1.7yrskeine Daten0.0013%
$ 42.1k
Jennifer Good
Independent Director5.4yrsUS$283.77k0.0049%
$ 159.1k
David W. McGirr
Independent Director9yrsUS$308.77k0.0049%
$ 159.1k
Edward Mathers
Lead Independent Director11.7yrsUS$328.77k0.014%
$ 464.9k
Lynn Tetrault
Independent Director3.9yrsUS$298.77k0.0049%
$ 159.1k
William Chin
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Elizabeth Stoner
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Michael Camilleri
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Lee Kaplan
Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
John Amatruda
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Stuart Arbuckle
Independent Director5.3yrsUS$301.27k0.0049%
$ 159.1k

5.4yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: RYTMDie Vorstandsmitglieder gelten als erfahren (5.4 Jahre durchschnittliche Amtszeit).